Introduction: The REGAL (RSV evidence-a geographical archive of the literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This third publication covers the risk and burden of RSV infection in infants with chronic lung disease (CLD), formerly called bronchopulmonary dysplasia (BPD). Methods: A systematic review was undertaken of publications between January 1, 1995 and December 31, 2015 across PubMed, Embase, The Cochrane Library, and Clinicaltrials.gov. Studies reporting data for hospital visits/ admissions for RSV infection among infants with CLD/BPD who were not prophylaxed, as well as studies reporting RSV-associated morbidity, mortality, and healthcare costs, were included. Burdens of disease data were compared with preterm infants without CLD/ Enhanced content To view enhanced content for this article go to www.medengine.com/Redeem/ F6E4F06044E2A44B. Electronic supplementary material The online version of this article (BPD, other high-risk groups and term infants.
INTRODUCTION
Respiratory syncytial virus (RSV) is the most important cause of severe respiratory infection in infants, accounting for over 3 million hospitalizations worldwide each year [1] .
Chronic lung disease (CLD) [formerly called bronchopulmonary dysplasia (BPD)] is the most common pulmonary complication of premature birth and increases the risk of RSV infection because it compromises lung function, distorts airway architecture, and promotes a pro-inflammatory milieu [2, 3] .
Severe RSV infection is associated with substantial morbidity and constitutes a considerable burden on healthcare systems [4] .
During the first 2 years of life, children with CLD/BPD are hospitalized for severe RSV at a higher rate than children born at term or more than 36 weeks gestational age (wGA) [5] [6] [7] . High-risk infants, including those with CLD/ BPD, also have a significantly higher intensive care unit (ICU) admission rate and length of stay (LOS) in hospital, and require more invasive and longer respiratory support than near-term or full-term infants [8] . There is currently no curative treatment for RSV infection. Treatment focuses primarily on supportive measures, such as providing supplemental oxygen and ensuring adequate hydration. RSV immunoprophylaxis is the mainstay of disease prevention and is indicated for specific children at high risk of developing serious disease. Current published guidelines recommend that RSV immunoprophylaxis is offered to infants with CLD/BPD who require medical therapy, such as supplemental oxygen, bronchodilator, diuretic or chronic corticosteroid treatment, within 6 months before the onset of the RSV season [9] [10] [11] [12] [13] [14] [15] .
New RSV therapeutics are currently being developed [16] . Therefore, it is important that there is a greater understanding of CLD/BPD as a condition leading to enhanced risk for severe RSV disease in order to improve preventative and management strategies, improve overall patient outcomes, and reduce the burden on 
METHODS

Study Objective
REGAL addresses seven specific research questions, covering: overall epidemiology, prematurity, CLD/BPD, congenital heart disease (CHD), long-term respiratory morbidity, other high-risk groups (e.g. Down syndrome), and prevention, management and future perspectives. The systematic reviews undertaken to answer each research question all use the same broad methodology, which has been described elsewhere [17] . The full protocol and generic search terms for the systematic reviews are available as part of the online 
Literature Search
In this systematic literature review, we sought to answer the key question: ''What is the morbidity, long-term sequelae and mortality of infants and young children with CLD/BPD due to severe RSV lower respiratory tract infection?''
The search for this systematic review included studies conducted in children B18 years old and published between January 1, 1995 and December 31, 2015. The target population was infants and young children with CLD/BPD who had 'proven' or 'probable' RSV and had or had not received RSV immunoprophylaxis. We retained only studies that reported RSV hospitalization (RSVH) and outcome data for infants and young children with CLD/BPD. However, studies with mixed pediatric populations hospitalized with RSV were also considered if there were sufficient data on infants and young children with CLD/ BPD. We limited publications by excluding meta-analyses and review articles. No language limits were set on the database searches, with the caveat that English translations of at least the abstract had to be available.
The following general terms and limits were used in MEDLINE (PubMed), EMBASE and the Cochrane Library: ''RSV'' OR ''respiratory syncytial virus'' AND ''lower respiratory tract infection'' OR ''bronchiolitis'' OR ''pneumonia'' AND ''chronic lung disease'' OR ''CLD'' OR ''bronchopulmonary dysplasia'' OR ''BPD'' AND ''hospitalization'' OR ''predisposition'' OR ''risk factor'' AND ''limits: human, child (birth to 18 years)''.
The [25] . CLD was defined as the continuous need for oxygen or respiratory support beyond 36 weeks post-menstrual age. (case-series). For each study, we also conducted a risk of bias assessment using the RTI Item Bank (score of 1 = very high risk of bias; score of 12 = very low risk of bias) for observational studies [28] .
Outcomes of Interest
Statement of Ethics Compliance
The analysis in this article is based on previously published studies and does not involve any new studies of human subjects performed by any of the authors.
RESULTS AND DISCUSSION
Articles Selected
From the initial literature search, we identified 2422 potentially relevant articles, of which 592 were duplicates ( Fig. 1 ). After phase 1 screening of the titles, 215 articles were considered and reviewed at abstract level, while 183 abstracts were rejected for not meeting the selection criteria, the majority because the studies did not focus on the population of interest (children 
Incidence of RSV Hospitalization
Studies from the United States, Canada and Europe have shown that infants with CLD/BPD, particularly those born prematurely, are at high risk for RSV-associated hospitalizations in the first 2 years of life [5, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . Across a number of studies, CLD/BPD had the highest or, in one case, the second highest, odds ratio (OR) of all independently significant risk factors for RSVH ( The reported incidence of RSVH in infants and young children with CLD/BPD who had not received RSV immunoprophylaxis varies between 12 and 46%, with 8 of 10 studies reporting an incidence of between 12 and 21% ( Taken together and discounting any heterogeneity across study populations, the average, weighted incidence of RSVH among 895 children with BPD/CLD in the identified studies ( Table 2 ) was 16.8%. When limited to studies with a definition of BPD/CLD as 'a continued need for oxygen at 36 wGA', the weighted mean was also 16.8%.
During the first 2 years of life, children with CLD/BPD are hospitalized for severe RSV at a higher rate than children born at term (C36 wGA) [5] [6] [7] . There is also some evidence that children with CLD/BPD have higher RSVH rates than those with CHD [7] or preterm infants without comorbidities [5, 7] . [5] . In contrast, a Finnish study [6] showed that whilst significantly higher RSVH rates were reported for children with CLD than [50] reported that preterm infants with CLD who require hospitalization for RSV infection have significantly greater morbidity in the first 2 years after birth than groups, including those with lower gestational age (€5555), and lower birth weight (€3895).
The authors observed that the differences in RSVH costs were mainly due to a longer duration of hospitalization [4] . Similarly, an observational, retrospective survey in Spain that analysed all RSVHs for children up to 5 years of age reported during the 1997-2011 period found that the average LOS and hospital costs were significantly higher in high-risk children,
including those with BPD [62] .
Estimates of RSVH costs have been reported in other studies, but these were not differentiated by patient characteristics such as CLD/BPD, making comparisons difficult.
Case-Fatality Rates
Few studies in the published literature on RSVH report case-fatality rates in infants with CLD/ BPD, and therefore it is difficult to ascertain from the available data the precise number of true RSV deaths in this high-risk population.
There are currently no data to suggest that case-fatality rates are higher in those children with CLD/BPD than in healthy term children or premature children without CLD/BPD [38, 51, 58, 63, 64] .
LIMITATIONS
There are two main limitations that merit consideration. First, the changing definitions of CLD/BPD over time may have affected the cross-comparisons that were generated between studies. Second, there was a lack of studies specifically investigating CLD/BPD. The majority of the studies identified comprised mixed populations, a proportion of which had CLD/BPD. In addition, other factors, such as improvements in medical practice over time and the type of RSV testing and surveillance systems employed will have influenced interpretation of the results. New studies should recognize that the established criteria for the definition of BPD [24, 65] may be used as a framework but are in a state of evolution [18, 22, 66] and, ideally, should include control for prematurity (stratified by gestational age) as another well-recognized risk factor for RSVH. This will enable more meaningful comparisons between studies and thereby a more reliable assessment of the true burden of RSV infection in this at-risk population. Most of our knowledge, however, has come from studies conducted more than a decade ago. These findings highlight the need for more up-to-date studies of the relative importance of CLD/BPD as a risk factor for severe RSV disease. Improved surveillance of this population will provide a more informative insight into the burden of disease to help improve outcomes and plan allocation of health care resources. Carbonell-Estrany has acted as an expert advisor and speaker for AbbVie and has received honoraria in this regard.
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